Dublin drug company’s value set to top €280 million in wake of US acquisition
Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion
Amryt, the Dublin-based orphan and rare disease drug firm, will have a market value of more than $300 million (€280 million) after its takeover of the US firm Aegerion.
Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion, which is emerging from bankruptcy protection in the US. The company is also seeking a listing on the US...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply